Why GlaxoSmithKline plc Is More Like Unilever plc Than AstraZeneca plc

The investment characteristics of GlaxoSmithKline plc (LON:GSK) are more like Unilever plc (LON:ULVR) than sector peer AstraZeneca plc (LON:AZN)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It used to be that investors in big pharma had a straight choice between GlaxoSmithKline (LSE: GSK) (NYSE:GSK.US) and AstraZeneca (LSE:AZN) (NYSE: AZN.US). They remain the two largest firms in the pharmaceutical sector of the London Stock Exchange, so that thinking still lingers in most investors’ minds.

But GSK’s CEO Andrew Witty has taken his company in a very different direction from Pascal Soriot at Astra. The two companies are no longer comparable, and it distorts the investment case to think of them that way.

The Unilever of healthcare

Mr Witty has de-emphasised the traditional big pharma strategy, whereby massive up-front investment in R&D aims to discover the next blockbuster drug to fund years of fat profits — most notably through the recent asset-swap with Novartis. He argues that Western governments will eventually baulk at the cost of healthcare for an ageing population, so the next generation of drugs won’t be so profitable. Perhaps the recent patent cliff scare also underlined the risky nature of prescription medicine.

So Mr Witty is emphasising global distribution of branded over-the-counter products and lower-margin vaccines, both of which play into growth in emerging market demand. Global consumer brands, low margins, emerging market growth, that sounds like the Unilever (LSE: ULVR) of healthcare. The two companies’ products even meet tangentially: there are markets where Unilever’s Signal toothpaste is up against GSK’s Aquafresh. The transition of GSK’s Horlicks from a Victorian tonic to India’s leading health drink mirrors the trajectory of Unilever’s Lifebuoy soap.

Biotech with a dividend

When Pascal Soriot took the helm in 2012 he committed AstraZeneca to just the science-heavy, R&D-led drug development that Andrew Witty is turning away from. Facing a steep and treacherous patent cliff, at the time I described Astra as like a biotech company with a dividend attached.

It still is, but three things have played to Mr Soriot’s advantage. To his credit, Astra’s scientists are delivering. Right now it’s creating a stir with immunotherapy, especially as a cancer cure. Secondly, biotech has become a fashionable sector. The thinking is that if you invent the drug, someone will pay for it. Thirdly, Pfizer’s aborted bid boosted Astra’s share price, which has remained elevated on the back of Mr Soriot’s bold confidence in Astra’s standalone earnings potential.

And the winner is…

Which of Mr Witty and Mr Soriot will eventually be proved right? The lesson for investors is that we won’t know until it’s too late. Investors shouldn’t stake too much on guessing what the future holds. Rather they should pick stocks — and plan portfolios — to suit their circumstances.

Personally I like boring but safe GSK. Stocks like GSK and Unilever, which offer bond-like security in their payout whilst locking in emerging market growth, make good cornerstone shares.

I’m wary of Astra’s valuation. Buoyed by lingering bid hopes, Mr Soriot’s big promises, and a biotech sector that could be in a bubble, I perceive bigger downside risk in the share price — but that’s countered by a bigger potential upside.

High yield

Both Astra and GSK offer good dividend yields, if little in the way of near-term dividend growth. That underlines their attraction to many investors, whether you want the income or want to re-invest and enjoy the compound growth in your holding.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tony Reading owns shares in GlaxoSmithKline and Unilever. The Motley Fool UK has recommended GlaxoSmithKline. The Motley Fool UK owns shares of Unilever. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

2 recession-resistant UK stocks I’d buy and hold for a decade!

Our writer details two UK stocks she believes could still continue to perform well in a recession and not feel…

Read more »

Back view of blue NIO EP9 electric vehicle
Investing Articles

Down 31% this year! Is now the moment to buy NIO stock?

NIO stock has moved sharply downwards in the past couple of months. Christopher Ruane likes the business potential -- but…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

2 dividend stocks I reckon could grow payouts for years to come!

This Fool is looking for dividend stocks and explains why these two picks could be primed to grow their payouts…

Read more »

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

Should I buy, sell, or hold my Rolls-Royce shares at £3.50?

This Fool considers what he should do with his Rolls-Royce shares following the FTSE 100 company's excellent full-year results last…

Read more »

Couple working from home while daughter watches video on smartphone with headphones on
Investing Articles

With a spare £280, here’s how I’d start buying shares this March

Our writer reflects on what he has learnt on the stock market to explain how he would start buying shares…

Read more »

Businesswoman calculating finances in an office
Investing Articles

Are these expensive FTSE 100 stocks actually brilliant bargains?

Paul Summers takes a closer look at two FTSE 100 stocks that could recover strongly in time, despite already carrying…

Read more »

Investing Articles

What might the recent Aviva share price performance tell me as an investor?

Christopher Ruane looks at how the Aviva share price has performed over the past 12 months and considers whether he…

Read more »

Investing Articles

Down by a quarter, is the BT share price a steal?

The BT share price has more than halved in the past five years. What is holding it down -- and…

Read more »